MedTrace Logo

Supplementation With L. Reuteri in H. Pylori Infected Adults

NCT01449500 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-10-10

No results posted yet for this study

Summary

To determine whether simultaneous use of L. reuteri ProGastria and proton pump inhibitors can eradicate H. pylori in humans in the absence of antibiotics.

Conditions

  • Dyspepsia
  • H. Pylori Infection

Interventions

DIETARY_SUPPLEMENT

L. reuteri

Chewable tablet, one tablet/day for 28 days

DIETARY_SUPPLEMENT

Placebo

Chewable tablet, one tablet per day for 28 days

Sponsors & Collaborators

  • BioGaia AB

    collaborator INDUSTRY

  • Lama Medical Care s.r.o.

    lead INDUSTRY

Principal Investigators

  • Ladislav Kuzela, MD · Gastroenterology Hepatology Centrum THALION, Poliklinika Mytna - 2.poscodie Mytna ul. 5, 811 07, Bratislava, Slovakia

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01449500 on ClinicalTrials.gov